Innovative drug development company Lynk Pharma recently announced the successful closing of a $50 million in its Series B financing. The round was led by Lilly Asian Ventures, with participation from New Alliance Capital and HeDa Investment., as well as existing investors Legend Capital and Med-Fine Capital who increased their investments.

CEC Capital Group served as the exclusive financial advisor for Lynk Pharma in this transaction.

This financing will be primarily used to advance multiple programs in Lynk Pharma's research and development pipeline through clinical Phase I and II trials, expand international business collaborations, and support pre-clinical development of new projects.

Founded in 2018, Lynk Pharma is a global leader in new drug development. Leveraging its team's world-class expertise in medicinal chemistry and small molecule clinical development, the company focuses on creating first-in-class (FIC) and best-in-class (BIC) small molecule drugs targeting autoimmune diseases, inflammation, and cancer. In just three and a half years since its establishment, Lynk Pharma has obtained IND approvals for three original research products in China and the United States, successfully advanced global clinical development, and in 2020, completed the transfer of overseas development rights for one product to a U.S. company, with initial and milestone payments totaling nearly $200 million. Additionally, the company introduced a potentially groundbreaking RAS project from Kobe University and RIKEN in Japan.